WaveMan
WaveMan · Company
DNA · Ginkgo Bioworks Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

DNA Ginkgo Bioworks (DNA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001830214
Quote by TradingView
Form 144 · 11
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
97
13F, latest reported quarter
Conversions, 180 days
18
Codes C/M, not in net · no price filed

What the filings say about DNA

Insiders, 180 days
-$1.4M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.2M
11 notices

Ginkgo Bioworks insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Ginkgo Bioworks Holdings, Inc. insiders sold a net $1.4M of stock across 693 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Kelly Jason R
See remarks
SELL
2026-10-21 SECtraded 2026-10-19
45,682
$463.4K
+2.9%
Context
  • 177 earlier Form 4 trades (code P or S) here by this insider (177 sales), the last on Apr 9, 2026.
  • The trade is 35.4% of the 129,065 shares held after it.
  • 3 other insiders sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks Kelly Jason R sold about $463.4K of DNA on Oct 19, 2026; 3 other insiders sold within 30 days and 97 funds added in the latest 13F quarter.
Shetty Reshma P.
See remarks
SELL
2026-10-21 SECtraded 2026-10-19
22,369
$226.9K
+2.9%
Context
  • 208 earlier Form 4 trades (code P or S) here by this insider (208 sales), the last on Apr 10, 2026.
  • The trade is 4.9% of the 453,951 shares held after it.
  • 3 other insiders sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks Shetty Reshma P. sold about $226.9K of DNA on Oct 19, 2026; 3 other insiders sold within 30 days and 97 funds added in the latest 13F quarter.
Shetty Reshma P.
See remarks
SELL
2026-10-21 SECtraded 2026-10-19
18,803
$190.7K
+2.9%
Context
  • 208 earlier Form 4 trades (code P or S) here by this insider (208 sales), the last on Apr 10, 2026.
  • The trade is 5.3% of the 356,329 shares held after it.
  • 3 other insiders sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks Shetty Reshma P. sold about $190.7K of DNA on Oct 19, 2026; 3 other insiders sold within 30 days and 97 funds added in the latest 13F quarter.
Coen Steven P.
See remarks
SELL
2026-10-21 SECtraded 2026-10-19
766
$7.8K
+2.9%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Oct 5, 2026.
  • The trade is 1.5% of the 50,168 shares held after it.
  • 3 other insiders sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See remarks Coen Steven P. sold about $7.8K of DNA on Oct 19, 2026; 3 other insiders sold within 30 days and 97 funds added in the latest 13F quarter.
Canton Barry
SELL
2026-10-21 SECtraded 2026-10-19
18,803
$190.7K
+2.9%
Context
  • 208 earlier Form 4 trades (code P or S) here by this insider (208 sales), the last on Apr 10, 2026.
  • The trade is 5.3% of the 356,329 shares held after it.
  • 3 other insiders sold within 30 days.
  • 97 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Canton Barry sold about $190.7K of DNA on Oct 19, 2026; 3 other insiders sold within 30 days and 97 funds added in the latest 13F quarter.
693 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 688 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.4M over 180 days
-$1.4M over 90 days · -$835.2K of it by a 10%+ holder
below 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
97 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
-25.1% year over year
below 71% of Pharma & Biotech
Margin
-183.8% net margin
below 64% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
14.6% of the float short (float per yahoo 2026-10-26) · 2.7 days to cover · settled 2026-09-30
What changed in the last 30 days
Oct 21See remarks Kelly Jason R sold $463.4K (Oct 19)
Oct 21Insider Canton Barry sold $417.6K (Oct 19)
Oct 21See remarks Shetty Reshma P. sold $417.6K (Oct 19)
Oct 19Officer Kelly Jason R filed to sell $463.3K by Oct 19 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 19Officer Shetty Reshma P. filed to sell $226.9K by Oct 19 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch DNA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-21.8%12M
-57%-32%-8%+17%2025-102025-122026-022026-042026-062026-082026-10 2026-04-10 · Canton Barry sold $802.0K2026-04-10 · Shetty Reshma P. sold $802.0K2026-04-09 · Kelly Jason R sold $702.5K2026-04-08 · Kelly Jason R sold $672.3K2026-10-19 · Kelly Jason R sold $463.4K2026-10-19 · Shetty Reshma P. sold $226.9K2026-10-19 · Canton Barry sold $226.9K2026-04-13 · Coen Steven P. sold $212.6K2026-10-19 · Shetty Reshma P. sold $190.7K2026-10-19 · Canton Barry sold $190.7K2026-04-08 · Shetty Reshma P. sold $91.2K2026-04-08 · Canton Barry sold $91.2K2026-04-09 · Shetty Reshma P. sold $83.9K2026-04-09 · Canton Barry sold $83.9K2026-10-05 · Coen Steven P. sold $36.0K2026-09-15 · HENRY CHRISTIAN O sold $35.4K2026-01-20 · Coen Steven P. sold $8.7K2026-10-19 · Coen Steven P. sold $7.8K2025-12-15 · Coen Steven P. sold $6.5K2026-07-17 · Coen Steven P. sold $5.9K2026-03-16 · Coen Steven P. sold $4.8K2026-04-17 · Coen Steven P. sold $2.6K2026-05-22 · Coen Steven P. sold $2.6K2026-08-24 · Coen Steven P. sold $2.3K2026-10-19 · Canton Barry filed to sell $190.7K2026-10-19 · Che Austin filed to sell $22.8K2026-10-19 · Che Austin filed to sell $162.9K2026-10-19 · Coen Steven P. filed to sell $7.8K2026-10-19 · Kelly Jason R filed to sell $463.3K2026-10-19 · Shetty Reshma P. filed to sell $226.9K2026-10-05 · Coen Steven P. filed to sell $36.0K2026-09-17 · Che Austin filed to sell $16.0K2026-09-15 · HENRY CHRISTIAN O filed to sell $35.4K2026-08-24 · Coen Steven P. filed to sell $2.3K2026-08-17 · Che Austin filed to sell $14.7K2026-07-17 · Coen Steven P. filed to sell $5.9K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DNA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,282,903 sh
$42.4M
VIKING GLOBAL INVESTORS LP
3,577,128 sh
$35.4M
Erste Asset Management GmbH
2,536,939 sh
$25.9M
BAILLIE GIFFORD & CO
2,391,649 sh
$23.7M
VANGUARD CAPITAL MANAGEMENT LLC
2,087,293 sh
$20.7M

Congress trades in DNA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DNA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Canton Barry
Filed 2026-10-19
$190.7K
Che Austin
Filed 2026-10-19
$22.8K
Che Austin
Filed 2026-10-19
$162.9K
Coen Steven P.
Filed 2026-10-19
$7.8K
Kelly Jason R
Filed 2026-10-19
$463.3K

DNA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ROBO Global Artificial Intelligence ETF
$2.9M position · as of 2026-07-31
0.7%
iShares Genomics Immunology and Healthcare ETF
$819.7K position · as of 2026-07-31
0.4%
Inspire Small/Mid Cap ETF
$822.0K position · as of 2026-05-31
0.3%
AQR Small Cap Multi-Style Fund
$665.6K position · as of 2026-06-30
0.2%
PIMCO RAE US Small Fund
$5.0M position · as of 2026-06-30
0.1%
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF
$3.2M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included. Not annual revenue (USASpending.gov).
Department Of Health And Human Services
TRAVELER-BASED GENOMIC SURVEILLANCE PROGRAM · 2025-02-28
$78.0M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · 1.
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.7M
$3.7M
$1.7M
-98%
-7%
2024
$1.2M
-$248.1K
$1.5M
-98%
-32%
2023
$262.0K
-$766.2K
$978.5K
-86%
-33%
2022
$262.5K
-$152.5M
$1.2M
-86%
-37%
2021
$380.7M
$237.5M
$210.4M
-32%
-16%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.4M sold by insiders over 180 days, 97 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRVRTXNUVLTWSTKYMR

DNA financials

Revenue growth
-25.1%
XBRL, annual
Net margin
-183.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$111.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+19.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$174.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+1.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$170.2M$227.0M$251.5M$477.7M
Operating income-$315.3M-$559.8M-$864.4M-$2.2B
Net income-$313.0K-$547.0K-$893.0K-$2.1M
EPS (diluted)n/an/an/an/a
Operating cash flow-$171.1M-$319.6M-$295.5M-$252.2M
Cash$167.2M$561.6M$944.1M$1.3B
SEC XBRL, fiscal years, as known on 2026-10-27

DNA Stock Sonar score 5/7 axes

Find similar shapesCompare

DNA ranks highest on profitability (83rd percentile) and institutional and government (67th), and lowest on insider conviction (16th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
83
Inputs
  • Return on equity+4.2% · 83 pct, sector of 545
  • Return on assets+1.9% · 83 pct, sector of 691
  • Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Growth
54
Inputs
  • Revenue growth, YoY-25.1% · 29 pct, sector of 505
  • Backlog growth, YoY+10.7% · 79 pct, sector of 40
Insider conviction
16
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.4M · 32 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
67
Inputs
  • Funds adding, latest quarter97 · 67 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
45
Inputs
  • Short interest, % of float+14.6% · 26 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.0% · 64 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DNA filings, in plain words

Are Ginkgo Bioworks insiders buying or selling DNA?

In the 180 days to 2026-10-27, Ginkgo Bioworks insiders were net sellers, a net $1.4M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of DNA?

Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.2M of stock; the latest, by Canton Barry, was filed 2026-10-19.

Read the full summary

In the 180 days to 2026-10-27, Ginkgo Bioworks insiders were net sellers of DNA, a net $1.4M across purchases and sales reported on Form 4 by 5 sellers. Most of that figure, $835.2K, came from a holder of 10% or more rather than an officer or director. None of the 11 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies